JP2025508832A5 - - Google Patents

Info

Publication number
JP2025508832A5
JP2025508832A5 JP2024550167A JP2024550167A JP2025508832A5 JP 2025508832 A5 JP2025508832 A5 JP 2025508832A5 JP 2024550167 A JP2024550167 A JP 2024550167A JP 2024550167 A JP2024550167 A JP 2024550167A JP 2025508832 A5 JP2025508832 A5 JP 2025508832A5
Authority
JP
Japan
Prior art keywords
dose
subject
administration
fraction
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508832A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/013836 external-priority patent/WO2023164143A1/en
Publication of JP2025508832A publication Critical patent/JP2025508832A/ja
Publication of JP2025508832A5 publication Critical patent/JP2025508832A5/ja
Pending legal-status Critical Current

Links

JP2024550167A 2022-02-25 2023-02-24 サイトカイン放出症候群の軽減のための投与レジメン Pending JP2025508832A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263313932P 2022-02-25 2022-02-25
US63/313,932 2022-02-25
US202263393212P 2022-07-28 2022-07-28
US63/393,212 2022-07-28
US202263420782P 2022-10-31 2022-10-31
US63/420,782 2022-10-31
US202263424210P 2022-11-10 2022-11-10
US63/424,210 2022-11-10
US202363440304P 2023-01-20 2023-01-20
US63/440,304 2023-01-20
PCT/US2023/013836 WO2023164143A1 (en) 2022-02-25 2023-02-24 Dosing regimens for mitigation of cytokine release syndrome with odronextamab

Publications (2)

Publication Number Publication Date
JP2025508832A JP2025508832A (ja) 2025-04-10
JP2025508832A5 true JP2025508832A5 (cg-RX-API-DMAC7.html) 2026-02-27

Family

ID=85778997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550167A Pending JP2025508832A (ja) 2022-02-25 2023-02-24 サイトカイン放出症候群の軽減のための投与レジメン

Country Status (11)

Country Link
US (1) US20230272118A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482524A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508832A (cg-RX-API-DMAC7.html)
KR (1) KR20240167457A (cg-RX-API-DMAC7.html)
CN (1) CN119156226A (cg-RX-API-DMAC7.html)
AU (1) AU2023224098A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244791A1 (cg-RX-API-DMAC7.html)
IL (1) IL315011A (cg-RX-API-DMAC7.html)
MX (1) MX2024010292A (cg-RX-API-DMAC7.html)
TW (1) TW202400228A (cg-RX-API-DMAC7.html)
WO (1) WO2023164143A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
CN103533943B (zh) * 2010-11-10 2018-02-13 安进研发(慕尼黑)股份有限公司 由cd3特异性结合结构域导致的不良作用的预防
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP3541843A1 (en) * 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
ES3009025T3 (en) * 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
TW202135860A (zh) 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗cd20x抗cd3雙特異性抗體之穩定調配物

Similar Documents

Publication Publication Date Title
TWI786044B (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
US8734799B2 (en) Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
JP2022050618A5 (cg-RX-API-DMAC7.html)
FI3886875T3 (fi) Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
JP2023524149A5 (cg-RX-API-DMAC7.html)
EP2218461A1 (en) CD40 antibody formulation and methods
JP2021528423A5 (cg-RX-API-DMAC7.html)
CN111629788A (zh) 用拮抗性抗-pd-1抗体治疗癌症的方法
US20240307541A1 (en) Methods for local and systemic treatment of cancers, tumors and tumor cells
JP2021512107A5 (cg-RX-API-DMAC7.html)
AU2017219596B2 (en) Chimeric canine anti-CD20 antibody
JP2023544407A5 (cg-RX-API-DMAC7.html)
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2021501217A (ja) 同種キメラ抗原受容体t細胞投与のための方法および組成物
Robak et al. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia
JP2023520771A5 (cg-RX-API-DMAC7.html)
JP2022502399A (ja) がんの治療のためのpd−1アンタゴニスト、atrインヒビター、および白金製剤の組合せ
JP2022541591A5 (cg-RX-API-DMAC7.html)
MX2011003335A (es) Composicion para tratar enfermedad.
JP2022513029A5 (cg-RX-API-DMAC7.html)
JP2025509567A5 (cg-RX-API-DMAC7.html)
JP2025502061A5 (cg-RX-API-DMAC7.html)
CA3227172A1 (en) Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2022521773A5 (cg-RX-API-DMAC7.html)